Table 1.
Demographic and clinical comparisons between young post-pubertal cis-men and cis-women and transgender cohorts
| Demographic: | Cis-men | Cis-women | Trans-men | Trans-woman | p Valuea |
|---|---|---|---|---|---|
| Number | 15 | 17 | 26 | 25 | – |
| Age, mean (SD) | 19 (2.73) | 18.94 (3.07) | 18.38 (0.57) | 18.44 (0.87) | 0.6316“ |
| BMI, mean (SD) | 23.99 (2.18) | 22.28 (3.59) | 24.75 (4.38) | 24.03 (4.92) | 0.4757“ |
| Ethnicity, number (%): | |||||
| White | 7 (47) | 8 (47) | 23 (88) | 22 (88) | 0.0008a |
| Asian | 5 (33) | 3 (18) | 0 (0) | 1 (4) | 0.0046a |
| Black | 1 (7) | 1 (6) | 1 (4) | 0 (0) | 0.6608a |
| Other | 2 (13) | 5 (29) | 2 (8) | 2 (8) | 0.1604a |
| Tanner stage at time of sample, n (%): | |||||
| Tanner stage 2-3 | 0 (0) | 0 (0) | – | – | >0.9999a |
| Tanner stage 4-5 | 15 (100) | 17 (100) | – | – | >0.9999a |
| Tanner stage at time of puberty block, n (%): | |||||
| Tanner stage 2-3 | – | – | 1 (4) | 11 (44) | 0.0008a |
| Tanner stage 4-5 | – | – | 25 (96) | 14 (56) | 0.0008a |
| Cross-sex-hormone treatment: | |||||
| Time on treatment (months), mean (SD) | – | – | 11.83 (7.40) | 12.04 (8.34) | 0.9234+ |
| Estradiol valerate (2-6 mg oral/day), n (%) | – | – | – | 19 (76) | – |
| Estradiol/Evorel patch (1.6–6.4 mg/patch), n(%) | – | – | – | 6 (24) | – |
| Estrogen serum level (pmol/L), median (IQR) | – | – | 75.50 (45.5–111.5) | 126.0 (44.0–256.0) | 0.0470+ |
| Sustanon (100–250 mg IM/4 weeks), n (%) | – | – | 23 (88) | – | – |
| Nebido (1,000 mg IM/12 weeks), n (%) | – | – | 2 (8) | – | – |
| Testogel (25 mg/day), n (%) | – | – | 1 (4) | – | – |
| Testosterone serum level (nmol/L), median (IQR) | – | – | 15.5 (6.1–25.8) | 0.4 (0.4–1.1) | <0.0001+ |
| Other medication, number (%): | |||||
| Contraception (combined pill) | – | 2 (12) | – | – | – |
| Anti-depressants | 0 (0) | 0 (0) | 4 (15) | 1 (4) | 0.0862a |
IM, intramuscular.
a
Fisher's exact (two groups) or chi-square (four groups) test, “one-way ANOVA, or +unpaired t test was used. For transgender individuals, the Tanner stage was their most recent Tanner stage prior to puberty blocking therapy.